Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin

Lode, H; Garau, J; Grassi, C; Hosie, J; Huchon, G; Legakis, N; Segev, S; Wijnands, G

dc.contributor.author	Lode, H	en
dc.contributor.author	Garau, J	en
dc.contributor.author	Grassi, C	en
dc.contributor.author	Hosie, J	en
dc.contributor.author	Huchon, G	en
dc.contributor.author	Legakis, N	en
dc.contributor.author	Segev, S	en
dc.contributor.author	Wijnands, G	en
dc.date.accessioned	2014-03-01T01:44:12Z
dc.date.available	2014-03-01T01:44:12Z
dc.date.issued	1995	en
dc.identifier.issn	0903-1936	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/24291
dc.subject	amoxycillin-clavulanic	en
dc.subject	community acquired pneumonia	en
dc.subject	erythromycin	en
dc.subject	sparfloxacin	en
dc.subject	treatment	en
dc.subject.classification	Respiratory System	en
dc.title	Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	1995	en
heal.abstract	The treatment of community-acquired pneumonia is empirical in most cases and must cover a wide range of potential pathogens, such as Streptococcus pneumoniae, including penicillin-resistant strains, Haemophilus influenzae and intracellular microorganisms. The objective of this double-blind, randomized, parallel group study was to compare the efficacy and safety of sparfloxacin (400 mg loading dose, followed by 200 mg o.d.) with that of oral amoxycillin-clavulanic acid (500/125 mg t.i.d.) or oral erythromycin (1 g b.i.d.), during 7-14 days in 808 patients with confirmed community-acquired pneumonia. The overall success rates for sparfloxacin (87%), amoxycillin-clavulanic acid (80%) and erythromycin (85%) were similar in evaluable patients, and the equivalence hypothesis used for the statistical analysis showed at least an equivalent efficacy for the three antibiotics tested. The analysis of microbiologically documented infections (40% of the patients) showed that overall success rates were similar for S. pneumoniae and H. influenzae infections. Treatment withdrawal was necessary in 3.5, 2.5 and 7.7% of the patients treated with sparfloxacin, amoxycillin-clavulanic acid and erythromycin, respectively. This study indicates that sparfloxacin was at least as effective as amoxycillin-clavulanic acid or erythromycin in the treatment of mild-to-moderate community-acquired pneumonia and that the adverse effects were similar in the three groups.	en
heal.publisher	MUNKSGAARD INT PUBL LTD	en
heal.journalName	EUROPEAN RESPIRATORY JOURNAL	en
dc.identifier.isi	ISI:A1995TN14600004	en
dc.identifier.volume	8	en
dc.identifier.issue	12	en
dc.identifier.spage	1999	en
dc.identifier.epage	2007	en